Skip to main content
Clinical Trials/IRCT2015020816830N2
IRCT2015020816830N2
Completed
未知

The effect of sensory- motor training on hand and upper extremity sensory and motor function in patients with Parkinson's disease

Vice Chancellor for research of Iran University of Medical Sciences,0 sites40 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Parkinson's disease.
Sponsor
Vice Chancellor for research of Iran University of Medical Sciences,
Enrollment
40
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Vice Chancellor for research of Iran University of Medical Sciences,

Eligibility Criteria

Inclusion Criteria

  • Inclusion Criteria:Having Parkinson's disease according to neurologist diagnosis; Having the disease progression level of 1 to 3 according to Hoehn and Yahr Scale; Having an acceptable level of cognitive function, i.e. score of more than 24 on the Mini Mental Status Examination (MMSE); To be eligible for sensory\-motor retraining (Having the light touch sensation at the level of acceptable mono\-filaments, i.e. 4\.31 and above in the fingertips and no severe problems of proprioception and discrimination sensation); Not having orthopedic problems (neurologic damages, fracture, tendon injuries), rheumatologic diseases (rheumatoid arthritis, osteoarthritis), neurologic diseases (stroke, multiple sclerosis) and other diseases such as diabetes, hepatitis and burns; Having the ability to read and write.

Exclusion Criteria

  • Lack of patient cooperation during the test; Not return for the testing after the intervention; Entering to the nonpharmacologic on\-off phase of the disease during the study according to neurologist diagnosis; Change in the pharmacologic regimen of the patient during the study; Inability to complete the activities of treatment interventions and progress to the harder levels of the intervention up to 70% of the protocol

Outcomes

Primary Outcomes

Not specified

Similar Trials